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Type 1 diabetes is an autoimmune disease initiated
by the invasion of pancreatic islets by immune cells
that selectively kill the b cells. We found that rodent
and human T lymphocytes release exosomes con-
taining the microRNAs (miRNAs) miR-142-3p, miR-
142-5p, and miR-155, which can be transferred in
active form to b cells favoring apoptosis. Inactivation
of these miRNAs in recipient b cells prevents exo-
some-mediated apoptosis and protects non-obese
diabetic (NOD) mice from diabetes development. Is-
lets from protected NOD mice display higher insulin
levels, lower insulitis scores, and reduced inflamma-
tion. Looking at the mechanisms underlying exo-
some action, we found that T lymphocyte exosomes
trigger apoptosis and the expression of genes
involved in chemokine signaling, including Ccl2,
Ccl7, andCxcl10, exclusively in b cells. The induction
of these genes may promote the recruitment of im-
mune cells and exacerbate b cell death during the
autoimmune attack. Our data point to exosomal-
miRNA transfer as a communication mode between
immune and insulin-secreting cells.
INTRODUCTION
Type 1 diabetes (T1D) is an autoimmune disorder characterized
by infiltration of the islets of Langerhans by immune cells and byselective elimination of the insulin-secreting b cells (Eizirik et al.,
2009). The infiltration of immune cells has been observed in non-
obese diabetic (NOD) mice, a well-known model of T1D (Ander-
son and Bluestone, 2005; Atkinson and Leiter, 1999), but also in
the islets of human diabetic donors (Atkinson et al., 2014; Krog-
vold et al., 2016; Lundberg et al., 2017). Patients suffering from
T1D require lifelong insulin administration to regulate whole
body glucose metabolism and homeostasis. Understanding
the dialogue between pancreatic b cells and the infiltrating im-
mune cells is crucial to promote the design of novel strategies
to prevent the development of this disease and/or to find a cure.
Part of the detrimental effects of the immune cells on b cell sur-
vival is known to be exerted through the release of pro-inflamma-
tory cytokines (Eizirik et al., 2009). However, lymphocytes were
recently found to release another class of immune mediators:
the exosomes (Thery et al., 2009). Exosomes are small extracel-
lular vesicles of 50–150 nm in diameter that originate from the
late endosomal pathway and are secreted in the extracellular
space upon fusion of multivesicular bodies with the plasma
membrane (Thery et al., 2009). Exosomes are released by
numerous cell types, including lymphocytes and pancreatic is-
lets (Guay and Regazzi, 2015; Robbins et al., 2016), and are pre-
sent in the blood and other body fluids (Weber et al., 2010).
These extracellular vesicles transport proteins, mRNAs, and
non-coding RNAs that can be transferred in active form to recip-
ient cells, suggesting an important role in cell-to-cell communi-
cation (Kosaka et al., 2010; Thomou et al., 2017; Valadi et al.,
2007; Zhang et al., 2010). Until recently, most of the studies on
exosomes were performed in in vitro or in ex vivo cell models,
but in vivo studies are now emerging. For example, the use in
mice of the Cre-loxP system or of a human-specific microRNA
(miRNA) elegantly demonstrated the transfer of the exosomeCell Metabolism 29, 1–14, February 5, 2019 ª 2018 Elsevier Inc. 1
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et al., 2017; Zomer et al., 2015). Of interest, the transfer of nucleic
acids by exosomes was found to be promoted by inflammatory
conditions (Ridder et al., 2014).
miRNAs constitute one of the main cargoes transported by
exosomes. These small non-coding RNAs are key post-tran-
scriptional modulators of gene expression and can be trans-
ferred in active form via exosomes to acceptor cells (Kosaka
et al., 2010; Montecalvo et al., 2012; Thomou et al., 2017; Valadi
et al., 2007; Zhang et al., 2015). miRNAs play an important role in
the control of b cell activities. Indeed, they are involved in the
differentiation and functional maturation of b cells and regulate
insulin secretion and cell survival (Dumortier et al., 2013; Eliasson
and Esguerra, 2014; Guay et al., 2011; Jacovetti et al., 2015;
Lynn et al., 2007). Deregulation of miRNA expression has
been associated with the development of T1D and T2D and
with age-associated decline in b cell proliferation (Filios and
Shalev, 2015; Guay and Regazzi, 2016; Nesca et al., 2013; Tugay
et al., 2016). Moreover, some miRNAs were found to induce
b cell dysfunction and death under inflammatory conditions in
both rodent and human islets (Grieco et al., 2017; Roggli
et al., 2012).
In thepresent study,we investigated the involvementofmiRNAs
in the initial phases of T1D development in NOD mice. We found
that islet insulitis is associatedwithanexosome-mediated transfer
of aparticular groupofmiRNAs, namelymiR-142-3p,miR-142-5p,
andmiR-155, from lymphocytes tobcells, resulting in theselective
death of the insulin-secreting cells. In vitro, inactivation of these
miRNAs inside the b cells protected them against apoptosis
induced by T lymphocyte exosomes and, in vivo, prevented T1D
development in NOD mice. Taken together, our results suggest
that the transfer of miRNAs mediated by exosomes released by
lymphocytes contributes to thedestructionof thebcells andcould
be part of the mechanisms leading to T1D development.
RESULTS
Increased Abundance of miR-142-3p, miR-142-5p, and
miR-155 in b Cells of Pre-diabetic NOD Mice
In a previous study, we performed a global miRNA expression
profiling of pancreatic islets of 4- and 8-week-old female NOD
mice (which correspond to control and pre-diabetic state,
respectively) to understand the role of miRNAs in b cell death
associated with T1D development (Roggli et al., 2012). At
8 weeks of age, NODmice are still normoglycemic but T lympho-
cytes are starting to infiltrate the islets (Roggli et al., 2012). The
miRNAs displaying the most important deregulation in the islets
of 8-week-old animals weremiR-142-3p/-5p, miR-150, andmiR-
155, which are known to control the activity of immune cells
(Dudda et al., 2013; Kroesen et al., 2015; Wu et al., 2007), but
are normally expressed at very low levels in insulin-secreting
cells. Indeed, we found that these miRNAs are much more
abundant in lymphocytes compared with islet cells (Figure S1A).
The expression of these miRNAs is modified to a much lesser
extent in the islets of age-matched diabetes-free NOD-SCID
mice (Figure 1A), indicating that the changes observed in pre-
diabetic mice are most likely linked to the development of the
disease. The increase in the levels of miR-142-3p/-5p and
miR-155 were detected also in fluorescence-activated cell sort-2 Cell Metabolism 29, 1–14, February 5, 2019ing (FACS)-sorted b cells of pre-diabetic NOD mice (Figure 1B),
confirming that the rise of these miRNAs occurs in insulin-
secreting cells. In agreement with previous findings in rat islets
(Bravo-Egana et al., 2012), the expression of these miRNAs
was not affected by incubation of control C57Bl/6N mouse islets
with the pro-inflammatory cytokines interferon g (IFN-g), tumor
necrosis factor alpha (TNF-a), and interleukin-1b (IL-1b) (Fig-
ure 1C). Therefore, the increase of miR-142-3p/-5p and miR-
155 in b cells in 8-week-old NOD mice is unlikely to be caused
by cytokines secreted by immune cells infiltrating the islets.
T Lymphocytes Release Exosomes ContainingmiR-142-
3p, miR-142-5p, and miR-155
Since immune cells release large amounts of exosomes, we hy-
pothesized that the rise of miR-142-3p/-5p, and miR-155 in islet
cells of pre-diabetic animals may result from an exosome-medi-
ated transfer favored by the proximity of T lymphocytes and
b cells during the initial phases of the disease. To explore this hy-
pothesis, we isolated by ultracentrifugation the vesicles released
by human Jurkat T cells (exoT) and by CD4+/CD25 T lympho-
cytes of NOD mice (exoNOD). Analysis of these preparations
by electronmicroscopy (Figures 2A and 2B) andNanoSight tech-
nology (Figures 2D and 2E) revealed the presence of round-
shaped small extracellular vesicles surrounded by a lipid bilayer
membrane with a diameter of 50–200 nm. These small extracel-
lular vesicles carried the characteristic exosomal markers CD81,
Alix, and Tsg101 (Thery et al., 2009) (Figure 2C). We next inves-
tigated if these small extracellular vesicles can be efficiently
internalized by insulin-secreting cells. After an overnight incuba-
tion, DiD-labelled exoT were found to be taken up by most cells
of the b cell line MIN6B1 (Figure 2F).
We next examined the miRNA content of T cell exosomes. All
three miRNAs, miR-142-3p/-5p, and miR-155, were found to be
present in the extracellular vesicles released by T lymphocytes
(Figures S1B and S1C). To ensure that these miRNAs are
confined inside exosomes, the samples were treated with
RNase. In contrast to a synthetic oligonucleotide (miR-29a
mimic) spiked into the samples, the level of the endogenous
miRNAs was not affected by the RNase treatment and were
degraded only when the exosome membrane integrity was
altered with the detergent Triton X-100 (Figure 2G).
Exosomal miRNAs from T lymphocytes Are Transferred
to b Cells
To assess whether the miRNAs present in the exosomes of
T lymphocytes can be transferred to b cells, dispersed mouse
islet cells were incubated with exoNOD for 72 hr (Figure 3A).
This treatment led to a significant increase in the abundance of
miR-142-3p/-5p and miR-155 in islet cells (Figure 3B). Similar
results were obtained when MIN6B1 or rodent islet cells were
exposed to exoT (Figures 3C and S2B). The sequence of miR-
142-3p and miR-142-5p is identical in humans and rodents
and, therefore, it is not possible to distinguish the miRNAs deliv-
ered via the exosomes from those endogenously produced in
mouse or rat b cells. In contrast, human miR-155 (hsa-miR-
155) differs by one nucleotide from its rodent counterparts
(Figure S2A) and can be readily distinguished by qPCR using
species-specific primers (Table S1). This strategy enabled us
to show that the rise of miR-155 observed in the receiving rodent
AB
C
Figure 1. Deregulation of miRNA Levels in b Cells of Pre-diabetic
NOD Mice
(A and B) Abundance of the indicated miRNAs in (A) islets of diabetes-
free SCID-NOD mice (n = 3 independent experiments) or (B) in FACS-
sorted b cells of NOD mice (n = 4 independent experiments) aged 4 and
8 weeks.
(C) Islets of control C57Bl/6N mice were incubated in the presence of pro-
inflammatory cytokines (IFN-g, TNF-a, and IL-1b) (n = 6 independent experi-
ments). miRNA levels were determined by qPCR and are expressed as fold
change versus 4 weeks or control (Ctl) condition (white bars). miR-146a was
used as a positive control for cytokine treatment.
Mean ± SD. *p < 0.05, **p < 0.01 by Student’s t test. See also Figure S1.
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miR-155 from the human Jurkat T cell line and not from an
increased synthesis of endogenous mmu-miR-155 (Figures 3C,
3D, and S2C). This finding was further confirmed using exo-
somes purified from CD4+/CD25 T cells of miR-155 knockout
mice (Figures S2D and S2E). Indeed, while the other miRNAs
were still increased in recipient MIN6B1 cells, the level of miR-
155 remained unchanged upon incubation with exosomes iso-
lated from miR-155 knockout mice (Figures S2F–S2H). To
demonstrate that hsa-miR-155 is transferred in active form in-
side the b cells, the receiving cells were transfected with a lucif-
erase sensor. As expected the incubation of MIN6B1 cells with
exoT for 48 or 72 hr led to a decrease in the luciferase activity
of the hsa-miR-155 sensor (Figure 3E), confirming that the
miRNA is transferred in active form in the receiving cells. Taken
together, these results provide evidence for an exosome-medi-
ated transfer of miRNAs from immune cells to b cells analogous
to that observed in other biological processes (Ridder et al.,
2014; Thomou et al., 2017; Zhang et al., 2015).
T Lymphocyte Exosomes Promote b Cell Apoptosis and
Induce the Upregulation of Genes Involved in Cytokine
and Chemokine Signaling
We next investigated the impact of T lymphocyte exosomes on
b cell function and survival. Incubation of b cells in the presence
of exoT did not affect insulin secretion or content (Figures S3A–
S3D) but led to a significant increase in cell apoptosis, which
was prevented by the pan-caspase inhibitor zVAD (Figures
3F, 3G, S3E, and S3F). The cytotoxic action of T cell exosomes
was reproduced in dispersed mouse islet cells incubated with
exosomes from T cells of NOD mice (Figure 3H). The apoptotic
effect of exoT cannot be attributed to the presence of residual
traces of cytokines released by lymphocytes. In fact, incubation
of b cells in the medium surrounding the purified exosomes did
not modify the level of the miRNAs and did not affect the sur-
vival of the cells (Figures S3G and S3H). To determine if this
process occurs also in humans, human islet cells were incu-
bated with exosomes (exo-hT) of CD4+ T cells isolated from
human blood donors. Similar to the findings obtained in
rodents, exposure of human islet cells to exo-hT resulted in
the transfer of miR-142-3p, miR-142-5p, and miR-155 (Fig-
ure 3I) and in an increase in cell death measured by Hoechst
or by TUNEL staining (Figures 3J and 3K).
Interestingly, the cytotoxic effect of the exosomes was
restricted to b cells. Indeed, the increase in apoptosis was re-
produced in FACS-sorted rat b cells (98% ± 2% purity) but not
in an a cell-enriched fraction (91% ± 4% a cells) (Figures 4ACell Metabolism 29, 1–14, February 5, 2019 3
Figure 2. Characterization of the Exosomes
Released by T lymphocytes
Exosomes were isolated from the culture media of
Jurkat cells (exoT) or NOD T lymphocytes (exoNOD)
by sequential centrifugation.
(A and B) Visualization of the extracellular vesicles
(arrows) released from (A) Jurkat cells or (B) NOD
T lymphocytes by electron microscopy. Scale bars,
100 nm.
(C) Analysis of the presence of the exosomal
markers Alix, CD81, and Tsg101 by western blotting
in our extracellular vesicle preparations. The
supernatant surrounding the exosome pellet after
ultracentrifugation was used as negative control
(Neg. Ctl).
(D and E) Analysis of the size distribution of (D) ExoT
and (E) ExoNOD vesicles using the NanoSight
technology.
(F) ImageStream flow cytometry analysis of MIN6B1
cells incubated with DiD-labelled ExoT (4 repre-
sentative pictures out of 20,171 cells analyzed).
Scale bars, 7 mm.
(G) miRNA levels in exoT. A miR-29a mimic, used as
positive control for RNase digestion, was spiked in
the ExoT preparation. The samples were then
treated or not (NT) with Triton X-100 (T) and incu-
bated with RNases (+R). miRNA levels were
measured by qPCR and are expressed as per-
centage of NT (n = 3 independent experiments).
Mean ± SD.
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selective uptake of the exosomes, we took advantage of the
auto-fluorescence properties of the rodent b cells (Kohler
et al., 2012). ImageStream flow cytometry, revealed that DiD-la-
belled exoT can be equally detected in auto-fluorescent b cells
and in non-fluorescent islet cells (Figure 4C). Consistent with
these findings, upon incubation with exoNOD miR-142-3p,
miR-142-5p, and miR-155 were transferred to both FACS-
sorted a and b cells (Figures 4D and 4E, respectively).
To elucidate the mechanisms through which T cell exosomes
exert their effect on b cells, we analyzed by microarray the
changes in the mRNA profile elicited in mouse islet cells by
exoNOD. Upon exposure to exoNOD, we detected about 90
upregulated and 20 downregulated genes (nominal p value <
0.05 and fold change >2) (Table S2). Pathway analysis revealed
a significant enrichment for genes involved in cytokine and che-
mokine signaling, including Ccl2, Ccl7, and IFNg (Figure S4A).
Several of these changes were confirmed by qPCR (Figures
5A and 5B). Using this technique, we also obtained evidence
for an increase in Cxcl10 (p = 0.05), a chemokine known to
be involved in T1D development (Frigerio et al., 2002; Roep
et al., 2010) (Figure 5A). The array data revealed also a strong
increase in the level of the eosinophil-associated ribonuclease4 Cell Metabolism 29, 1–14, February 5, 2019family members, Ear1, Ear2, and Ear12
(Table S2). The role of these RNases in
b cells has so far not been explored but,
in other cell types, Ear proteins have cyto-
toxic and chemoattractant effects (Gupta
et al., 2013; Rosenberg, 2015). Interest-
ingly, overexpression of miR-142-3p/-5pand miR-155 in mouse islet cells led to an increase in the level
of Ccl2, Ccl7, and Cxcl10 similar to that observed upon incuba-
tion with exoNOD (Figure 5C), indicating that at least part of the
effect of the exosomes is mediated by the transfer of these
miRNAs. Exposure of human islets to the exosomes released
by activated human CD4+ T cells (exo-hT) led to a similar in-
crease in CCL2, CCL7, and CXCL10 (Figure 5D), indicating
that this phenomenon is not restricted to rodents.
To better understand the cell-specific apoptotic effect of exo-
somes, we incubated FACS-sorted a and b cells with exoNOD
for 72 hr.We found thatmiRNAs are transferred to both cell types
(see Figures 4D and 4E), but the rise ofCcl2 andCxcl10was only
observed in b cells (Figure 5E). A similar trend was observed for
Ccl7. These results suggest that the selective effect of the exo-
somes is likely to be caused by the activation of cell death
signaling pathways operating predominantly in b cells.
Several of the differentially expressed genes are elicited in
response to the activation of nuclear factor kB (NF-kB), a
signaling pathway known to trigger b cells apoptosis (Melloul,
2008). Consistent with this observation, exposure of MIN6B1
cells to ExoT was associated with a nuclear translocation of
NF-kB (Figures 5F and S4). The fraction of cells in which NF-
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(Figure 5F). Interestingly, the translocation of the transcription
factor could be reproduced by directly overexpressing miR-
142-3p, miR-142-5p, or miR-155 (Figure 5F), confirming a causal
link with the transfer of these miRNAs.
Inactivation of miR-142-3p, miR-142-5p, and miR-155
Prevents Exosome-Induced Cell Death
To determine whether the transferred miRNAs contribute to the
deleterious effect of T cell exosomes on b cell activities, we
directly increased their level using miRNA mimics (Figure S5A
and S5C). While none of the tested miRNAs affected insulin
secretion or content (Figures 6A and S5B), overexpression of
miR-142-3p, miR-142-5p, or miR-155 increased apoptosis
both in MIN6B1 (Figure S5D) and in rat islet cells (Figure 6B). If
the transfer of specific miRNAs from T cells to b cells contributes
to apoptosis induced by exosomes, then inactivation of these
miRNAs in receiving cells should prevent cell death. We first veri-
fied this hypothesis in vitro using anti-miRs that specifically block
the action of the transferredmiRNAs. Anti-miRs will not avoid the
transfer of the miRNAs but will sequester them upon delivery
inside the recipient b cells, blocking the interaction with their
targets. Transfection of islet cells with anti-miR-142-3p, anti-
miR-142-5p, or anti-hsa-miR-155 attenuated the rise of these
non-coding RNAs (Figures S6A–S6C) and prevented apoptosis
induced by exoT (Figure 6C). This effect was specific to exo-
some-induced apoptosis since these anti-miRs failed to protect
b cells exposed to pro-inflammatory cytokines (Figures S6E–
S6G). While decreasing the level of endogenous miR-155, trans-
fection of rat islet cells with an anti-miR against murine miR-155
did not prevent cell death (Figures 6C and S6D). Taken together,
these results suggest that miR-142-3p, miR-142-5p, and miR-
155 transferred by exosomes from T lymphocytes to b cells
induce recipient cell death.
Injection of a miRNA Sponge in 4-Week-Old NOD Mice
Prevents T1D Development
Our findings suggest that a transfer of a subset of miRNAs from
immune cells to b cells taking place during the initial phases of
T1D could potentially contribute to the development of the dis-
ease. To assess the pathophysiological relevance of this exo-
some-mediated cell-to-cell signaling in vivo, we engineered an
Adeno-associated virus (AAV) producing a GFP transcript con-
taining multiple binding sites for miR-142-3p/-5p, miR-150,
and miR-155. This ‘‘miRNA sponge’’ is driven by the insulin pro-
moter and specifically sequesters these miRNAs once delivered
inside the b cells (Figure 7A) (Ebert et al., 2007). As at the begin-
ning of our study it was not clear whether miR-150 would beFigure 3. T Cell Exosomes Transfer miRNAs to b Cells and Induce the
(A) Schematic representation of the in vitro exosome transfer experiments. CD4+
human blood samples) and cultured for 72 hr in the presence of CD3CD28 activa
ultracentrifugation and added to recipient islet cells.
(B–K) Mouse islet cells (B andH) were incubated with exoNOD, rat islet cells (C, D,
experiments) for 48–72 hr. At the end of the incubation, miRNA abundance wasm
as relative fluorescent units (RFU) if the miRNA was undetectable under control c
with the hsa-miR-155 sensor and treated with exoT for 48 or 72 hr (a.u., arbitra
pycnotic nuclei upon Hoechst staining without or with the pan-caspase inhibitor
Mean ± SD. *p < 0.05, **,##p < 0.01 by Student’s t test or by one-way ANOVA, Du
Table S1.
6 Cell Metabolism 29, 1–14, February 5, 2019involved in diabetes development, we decided to also include
in the construct the binding site of this miRNA. The miRNA
sponge or a control AAV lacking the miRNA binding sites were
intraperitoneally injected in 4-week-old female NODmice. As ex-
pected, GFP mRNA and protein expression was detected in the
islet of 8-week-old mice injected with the sponge or the control
AAV (Figures S7A and S7B). Importantly, GFP was not detected
in the exocrine pancreas and in immune cells invading the islets,
confirming the specificity of the insulin promotor (Figure S7C). At
8 weeks of age, both control and sponge-treated NODmice dis-
played similar body weights, plasma glucose levels and glucose
tolerance, and showed low levels of lymphocyte infiltration (Fig-
ures S7D–S7F, S8A, and S8B). However, while at 32 weeks of
age 80% of the control mice became diabetic, only 40% of the
animals receiving the miRNA sponge developed the disease
(Figure 7B). Histological analysis of the pancreases at the time
of sacrifice revealed that these disease-free mice retain a higher
insulin volume compared with the animals developing diabetes
(Figure 7C). Moreover, their islets more often displayed low insu-
litis scores (Figure 7D). This was not associated with an increase
in FoxP3-positive Treg lymphocytes suggesting a decrease in
inflammation rather than changes in the cell populations of the
immune infiltrate (Figure S8C). Consistent with this hypothesis,
we found reduced levels of CXCL10 in islet cells (Figure 7E). In
line with our in vitro observations, CXCL10 was more frequently
found in insulin-positive cells compared with glucagon-positive
cells, and the expression of this chemokine in b cells was signif-
icantly reduced in sponge-protected mice (Figure 7E). CXCL10
levels were already lower in sponge-treated 8-week-old mice
compared with control animals suggesting a diminished chemo-
attractant ability of the b cells expressing the miRNA sponge
(Figure 7F).
Taken together, these in vivo data support the relevance of the
exosome-mediated transfer of genetic material in the autoim-
mune reaction and indicate that the inactivation of miR-142-
3p/-5p, miR-150, and miR-155 in b cells is able to protect NOD
mice against T1D development.
DISCUSSION
The autoimmune attack of b cells is a hallmark of T1D, but the
events culminating in the specific loss of the insulin-secreting
cells remain poorly understood. In the present study, we provide
evidence for the involvement of an exosome-mediated transfer
of miRNAs from T lymphocytes to b cells in the initial phases of
T1D development. Exosomes have been shown to participate
to the etiology of other autoimmune disorders (Robbins et al.,
2016; Turpin et al., 2016). Indeed, these small extracellularir Death
CD25 T lymphocytes were isolated from mouse spleen (or alternatively from
tion beads, IL-2 and IL-12. Exosomes were isolated from the culture media by
F, andG) with exoT and human islet cells (I–K) with exo-hT (n = 4–5 independent
easured by qPCR and was expressed as fold changes versus Ctl (B, C, and I) or
ondition (D). (E) Luciferase activity was measured in MIN6B1 cells transfected
ry units). (F–H and J) Apoptosis was assessed by scoring the cells displaying
zVAD, or (K) using TUNEL assay.




Figure 4. T Cell Exosomes Specifically
Induce b Cell Death
(A and B) FACS-sorted rat islet fractions enriched
for (A) b cells or (B) a cells were incubatedwith exoT
for 72 hr. Apoptosis was assessed by scoring the
cells displaying pycnotic nuclei upon Hoechst
staining in (A) n = 5 independent experiments and in
(B) n = 3 independent experiments.
(C–E) Analysis by ImageStream flow cytometry of
rat islet cells incubated with DiD-exoT. Two
representative images out of 10,089 cells analyzed
are shown (C). FACS-sorted rat islet fractions en-
riched for b cells (D) or a cells (E) were incubated
with exoNOD for 72 hr. miRNA levels were
measured by qPCR and are expressed as fold
changes versus Ctl (n = 3 independent experi-
ments).
Mean ± SD. *p < 0.05, **p < 0.01 by Student’s t test.
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participate in the formation of immune complexes and synapses,
and contribute to the maintenance of the inflammatory status.
We observed that exposure of b cells to exosomes released
from T lymphocytes does not alter their secretory capacity but
increases their apoptotic rate. An important feature of the
autoimmune attack of pancreatic islets is the selective killing of
the b cells. Interestingly, the exosomes released by T cells repro-
duce this b cell-specific event and have no deleterious impact
on a cells. This cell selectivity cannot be explained by a specific
targeting of the exosomes to b cells, since these small extracel-
lular vesicles are internalized by other islet cell types. b cell-spe-
cific apoptosis is most likely the result of the activation by
exosomes of cell death pathways operating only in insulin-
secreting cells. Human and rodent a cells have been reportedCeto be resistant to metabolic and immune
stresses that induce b cell death (Marroqui
et al., 2015; Takeda et al., 2012; Vasu
et al., 2015). In agreement with this hy-
pothesis, Ccl2, Ccl7, and Cxcl10 were
solely increased in b cells and not in a cells
upon exosome treatment. Moreover, in
NOD mice developing diabetes CXCL10
was more frequently detected in insulin-
positive cells than in glucagon-posi-
tive cells.
The exosome cargo includes proteins
and nucleic acids, in particular miRNAs.
We previously identified a subset of
miRNAs that are highly abundant in the
islets of pre-diabetic NOD mice (Roggli
et al., 2012). We show here that this
increase cannot be explained by the
exposure of b cells to pro-inflammatory
cytokines but is rather the result of an
exosome-mediated shuttling of miR-142-
3p/-5p and miR-155 from T lymphocytes
to b cells. Our data provide strong evi-
dence indicating that the transfer of these
miRNAs is instrumental to induce b celldeath. Indeed, overexpression of these miRNAs is sufficient to
induce b cell apoptosis, and blockade of these miRNAs inside
the b cells prevents apoptosis induced by T cell exosomes but
not by pro-inflammatory cytokines. Individually, none of the pre-
dicted targets of the miRNAs is able to explain the activation of
NF-kB or the observed increase in apoptosis. This is not surpris-
ing becausemiRNAs are known to function by inducing relatively
small changes in the expression of a large number of genes
rather than by causing major changes in the level of a single tran-
script. Computational analysis suggests that miR-142-3p, miR-
142-5p, and miR-155 share some common targets (Table S3),
some of which are known to participate to the regulation of
cytokine and/or NF-kB signaling. Thus, the signaling cascades
activated in response to an increase of these miRNAs may





Figure 5. Regulation of b Cell Gene Expression by T Cell Exosomes
(A and B) Confirmation by qPCR of gene expression changes observed by global microarray profiling of mouse islet cells incubated with exoNOD. The results are
expressed (A) as fold changes or (B) as RFU, Ifng being undetected under control conditions (n = 4 independent experiments).
(legend continued on next page)
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Figure 6. Effects of miR-142-3p/-5p and
miR-155 Deregulation on b Cell Function
and Survival
(A and B) Dispersed rat islet cells were transfected
with the indicated miRNA mimics. (A) Insulin
secretion in response to 2 or 20 mM glucose (2G or
20G) wasmeasured by ELISA (n = 3–6 independent
experiments). (B) Apoptosis was assessed by
Hoechst staining (n = 4 independent experiments).
Cytokine mix (Cyt) was used as positive control.
*p < 0.05, **p < 0.01 by Student’s t test.
(C) Dispersed rat islet cells were transfected with
the indicated anti-miR and incubated with exoT for
72 hr. At the end of the incubation period,
apoptosis was determined by scoring the cells
displaying pycnotic nuclei upon Hoechst staining
(n = 4 independent experiments).
Mean ± SD. *,#p < 0.05. **,##p < 0.01 by one-way
ANOVA, Dunnett’s post hoc test.
See also Figures S5 and S6.
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miR-142-5p, and miR-155 were all found to modulate NF-kB ac-
tivity, pointing to a common mode of action. Thus, although the
overexpression of each individual miRNA can potentially lead to
cell death, the effect of the T cell exosomes is likely to result from
the synergistic action of the three miRNAs. In fact, blockade of
any of the three transferred miRNAs was sufficient to prevent
exosome-induced apoptosis.
We were able to prove the relevance of this novel exosome-
mediated cell-to-cell communication mode for T1D devel-
opment by taking advantage of an AAV construct containing
multiple binding sites for miR-142-3p/-5p, miR-150, and miR-
155. Indeed, NODmice injectedwith thismiRNA sponge showed
a 50% reduction in the incidence of the disease compared with
the control group. As expected, this protection against T1D
development was accompanied with a higher islet insulin volume
and lower insulitis scores. Whether the protective effect of the
miRNA sponge is limited to b cell death or also prevents the initial
steps of the disease remains to be defined. Since an efficient
transfer of miRNAs from lymphocytes to b cells involves the
close proximity of the two cells, this event is very unlikely to
constitute the initial trigger of the disease. However, once the
autoimmune reaction has been initiated by viral antigens, auto-
antigens, or other inflammatory mediators, and immune cells
are recruited to the islets, b cell chemokine production resulting
from the transfer of the miRNAs may contribute to maintain and
further exacerbate the insulitis. This scenario is consistent with
the reduced immune infiltration of the islets observed in mice(C–E) Gene expression levels were measured by qPCR in (C) dispersed mouse islet cells transfected with m
human islet cells incubated with exo-hT, and (E) FACS-sorted rat islet fractions enriched for a or b cells incuba
changes (n = 4 independent experiments).
(F) Nuclear translocation of NF-kB inMIN6B1 cells incubated with exoT or pro-inflammatory cytokines (IFN-g
miR-142-5p, and miR-155 mimics (n = 3–4 independent experiments).
Mean ± SD. *p < 0.05, **p < 0.01 Student’s t test. See also Figure S4 and Table S2.
Cetreated with the miRNA sponge. To pre-
cisely define the contribution of exo-
some-mediated miRNA transfer to thedifferent stages of the diseases, large cross-sectional studies
monitoring the impact of the miRNA sponge on insulitis progres-
sion and b cell loss during the natural course of diabetes will be
needed.
Interestingly, Ying et al. (2017) recently demonstrated the
detrimental effect of miR-155 released in exosomes frommacro-
phages residing in adipose tissue of obese mice on systemic in-
sulin sensitivity and glucose tolerance. These metabolic markers
were improved in miR-155 knockout animals. Therefore, the
release by immune cells of miR-155 in exosomes may possibly
be implicated in the etiology of both T1D and T2D.
The precise mechanisms through which the exosomes of
T lymphocytes trigger b cell death remain to be fully established.
In vitro, activation of NF-kB signaling as well as the induction of
several members of the Ear family that are cytotoxic in other cell
types (Gupta et al., 2013; Rosenberg, 2015) may contribute to
the increase in the apoptotic rate observed upon exposure to
exosomes. In vivo, T lymphocyte exosomes may be part of the
mechanisms favoring islet inflammation, insulitis progression,
and T1D development. Under inflammatory conditions, b cells
are known to produce chemokines such as CCL2 and
CXCL10, which are believed to favor insulitis and diabetes devel-
opment (Frigerio et al., 2002; Martin et al., 2008). The expression
of these inflammatory mediators was also observed in pancre-
atic sections or in islet samples of human T1D donors (Eizirik
et al., 2012; Roep et al., 2010). In our study, global expression
profiling of mouse islets incubated with exosomes from NOD
T effector cells revealed the upregulation of several genes linkediR-142-3p, miR-142-5p, and miR-155 mimics, (D)
ted with exoNOD. The results are expressed as fold
, TNF-a, and IL-1b), or transfected with miR-142-3p,
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Cxcl10, and Ifng. Interestingly, Ccl2 was found to modulate
NF-kB signaling in MIN6 cells (Cai et al., 2011) and other cell
types (Viedt et al., 2002; Viedt and Orth, 2002). At least part of
these gene expression changes may be driven by the transfer
of miRNAs from immune cells to b cells. Indeed, overexpression
of miR-142-3p, miR-142-5p, and miR-155 in b cells led to an in-
crease inCcl2,Ccl7, andCxcl10 expression and favored nuclear
translocation of NF-kB. CXCL10 levels are reduced in b cells of
NODmice injectedwith the AAV-sponge and protected fromdia-
betes development. Therefore, in vivo, the exposure to exo-
somesmay exacerbate the release of cytokines and chemokines
from b cells elicited in response to inflammatory mediators pro-
duced by T lymphocytes, favoring insulitis progression and T1D
development.
The exosome-mediated dialogue between lymphocytes and
b cells may operate in both directions. Indeed, these vesicles
were reported in other immune diseases to activate T lympho-
cytes either directly or indirectly via the antigen-presenting cells
(Turpin et al., 2016). The release of exosomes from human and
rodent islet cells or by insulinoma cell lines has been reported
by several laboratories (Bashratyan et al., 2013; Cianciaruso
et al., 2017; Guay et al., 2015; Sheng et al., 2011). Sheng et al.
(2011) observed that injection of exosomes produced by MIN6
cells in NOR mice favors lymphocyte islet infiltration and in-
creases insulitis. In vitro, exosomes from MIN6 cells were found
to trigger both innate and antigen-specific signals by inducing
lymphocyte proliferation and by activating autoreactive T helper
1 cells and marginal zone-like B cells (Bashratyan et al., 2013;
Sheng et al., 2011). The precise mechanisms through which
b cell exosomes trigger the immune response remain to be
unveiled. Exosomes released by rat and human islet cells
contain three autoantigens linked to T1D, namely GAD65, IA-2,
and proinsulin, and are taken up by dendritic cells causing their
activation (Cianciaruso et al., 2017). The presence of these auto-
antigens in exosomes released by b cells could explain how
these proteins become the target of the immune system even
if they are localized mainly inside the cells. Indeed, exosome-
mimetic liposomes transporting GAD65 could favor antigen pre-
sentation and T cell activation. Finally, other components of b cell
exosomes were also involved in stimulation of antigen-present-
ing cells (Cianciaruso et al., 2017).
In the present study, we focused on miRNAs transferred from
CD4+ T effector cells to b cells. However, other immune cells infil-Figure 7. Inactivation of miR-142-3p/-5p, miR-150, and miR-155 in b C
(A) Schematic representation of the AAVproducing aGFP transcript containingmu
driven by the insulin promotor (RIP). The AAV-sponge (Sp) or a control AAV lacking
4 weeks.
(B) Diabetes-free animals displaying a glycemia below 14 mM, in the group of m
3 independent experiments, p = 0.0267, by log rank test.
(C) Insulin volume determined by immunostaining in AAV-sponge-injected animals
(Sp-protected [Sp-prot]) until 32 weeks of age (n = 70 pancreatic sections, from
(D) Insulitis score measured at the time of sacrifice in the pancreases of AAV-spo
diabetes development (n = 3 mice per group).
(E) Colocalization of CXCL10 (red) with insulin (green, yellow arrows) or glucago
developing (SP-NP) or not developing (SP-prot) diabetes.
(F) CXCL10 levels (red) normalized to islet insulin volume (green) in 8-week-old NO
DAPI (blue) (E) n = 35, and (F) n = 180 pancreatic sections, from 3 different mice
Mean ± SEM. **p < 0.01 by Mann-Whitney U test or by one-way ANOVA, Tukey’trating the islets release exosomes with a similar miRNA content.
For example, miR-150 and miR-155 are released in exosomes
originating from monocytes and macrophages, respectively,
and have functional impacts on recipient cells (Ying et al.,
2017; Zhang et al., 2010). The composition of the immune infil-
trate and the origin of the exosomes may differ with the progres-
sion of the disease. Our data do not exclude the contribution of
exosomes produced by other immune cells infiltrating the islets
in b cell dysfunction and loss. We believe that the transfer of
miRNAs to b cells during T1D development is mainly promoted
by the close proximity of the activated immune cells that invade
the islets. However, the amount and the composition of the
exosome cargo varies depending on the activation state of the
immune cells (Gutierrez-Vazquez et al., 2013; Okoye et al.,
2014; van der Vlist et al., 2012). Indeed, the exosomes released
by active T cells were reported to contain higher levels of miR-
142-3p (Sukma Dewi et al., 2017). In vivo, it is possible that the
presence of autoreactive T cell receptors or of other specific
components at the exosome surface of infiltrating immune cells
may facilitate the fusion with the b cells and the delivery of the
miRNAs. Moreover, the exosomes released by immune cells
may carry additional molecules potentially affecting the activity
of the target cells, including other RNAs, proteins, and lipids.
A better understanding of the mechanisms governing the target-
ing of the exosomes and of the cargo they deliver will not only
help elucidating the mechanisms triggering T1D but may also
shed new light on the etiology of other autoimmune diseases.
Our findings have relevant implications for the design of better
approaches to prevent T1D development. Strategies to avert the
loss of b cells will need to take into account the existence of this
newly discovered cell-to-cell signaling mechanism. The exo-
some-mediated transfer of miRNAs with harmful effects on
b cells is probably exacerbating the deleterious impact of pro-in-
flammatory cytokines released by the invading immune cells,
and is likely to synergize with other well-described events
involved in the autoimmune reaction. Thus, therapeutic interven-
tions tackling several aspects of the immune attack would prob-
ably be more effective in protecting the b cells.
Limitations of the Study
In this study, we showed that a viral construct blocking the activ-
ity of a group of miRNAs transferred from lymphocytes to b cells
reduces the incidence of T1D in NODmice. Although these mice
constitute a widely used model of T1D and reproduce many ofells of NOD Mice Reduces the Incidence of T1D
ltiple binding sites formiR-142-3p/-5p, miR-150, andmiR-155 (miRNA sponge)
the miRNA binding sites (Ctl) were injected intraperitoneally in NODmice aged
ice injected with the AAV-sponge and with AAV-Ctl. Total of n = 15–16 mice,
that developed diabetes (Sp-not protected [Sp-NP]) or remained disease-free
3 different mice per group). **p < 0.01 by Mann-Whitney U test.
nge-injected mice that were protected (Sp-prot) or not protected (Sp-NP) from
n (blue, red arrows) in 32-week-old NOD mice injected with the AAV-sponge
Dmice injected with AAV-Ctl (Ctl) or AAV-sponge (Sp). Nuclei were stained with
per group.
s post-hoc test. See also Figures S7 and S8.
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additional investigations will be needed to assess the transla-
tional potential of our findings. In fact, human T1D is character-
ized by less-pronounced intra-islet infiltration, and several
immunotherapies preventing the disease in NOD mice were
found to be inefficient in humans (Kolb and von Herrath, 2017).
Future experiments will also have to investigate the efficacy of
the treatment at different stages of the disease. Indeed, in this
study the miRNA sponge was injected prior to the initiation of
the autoimmune reaction and we ignored whether the treatment
would be equally efficient after intra-islet infiltration has
occurred. This information will be essential to evaluate the ther-
apeutic potential for human T1D of strategies targeting the exo-
some-mediated process unveiled in this study.
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psicheck1 vector - ctl Promega Cat#: C8011
Software and Algorithms
Volocity 6.3 software Perkin Elmer RRID:SCR_002668
Graph Pad Prism 6 Graph Pad software https://www.graphpad.com/scientific-
software/prism/
Please cite this article in press as: Guay et al., Lymphocyte-Derived Exosomal MicroRNAs Promote Pancreatic b Cell Death and May Contribute to
Type 1 Diabetes Development, Cell Metabolism (2018), https://doi.org/10.1016/j.cmet.2018.09.011CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact,
Dr. Romano Regazzi (romano.regazzi@unil.ch).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Rodent
All animal procedures were performed in accordance with the NIH guidelines and protocols were approved by the Swiss Research
Councils and Veterinary Offices or the Ethical Committee for Animal Experiments of the University of Groningen. Male Wistar rats
(200-250g) and 4-8 weeks old female NOD/ShiLtJ mice were obtained from Charles River Laboratories (L’arbresle, France). Male
C57Bl/6N mice (12-15 week-old) and 4 and 8 weeks-old female NOD scid mice (NOD.CB17-Prkdcscid/Rj) were from Janvier
Labs (Le Genest St-Isle, France). miR-155 knockout mice (miR-155-/-) were from Jackson Laboratories (Jax 007745).
Human Islets
Human islet preparation were obtained from Tetu-Bio (Lot HP-18157-01, Germany) or from the Centre d’Etude Europe´en pour le
Diabe`te in Strasbourg (isolation protocol authorization for scientific research #PFS12-0013). Dissociated islet cells were cultured
in CMRL medium (Invitrogen) supplemented with 10% fetal calf serum (Gibco), 10 mM HEPES pH 7.4, 100 mg/mL streptomycin
and 100 IU/mL penicillin and 2 mmol/l glutamine. Detailed information about human islet donors are provided in Table S4 and in
Key Resources Table.
Cell Lines
Jurkat cells (J77 clone 20 fromO. Acuto) (Rebeaud et al., 2008) were cultured in RPMI 1640medium supplementedwith 10% fetal calf
serum (previously depleted from serum-exosomes), 50 mg/mL streptomycin and 50 IU/mL penicillin at densities comprised between
0.2 and 1 x 106 cells/mL. Jurkat culture media was collected each two to three days for exosome isolation. MIN6B1 cells, a murine
insulin-secreting cell line (Lilla et al., 2003), were cultured at a density of 1.5 x 105 cells/cm2 in DMEM-GlutaMAXmedium (Invitrogen)
containing 25mMglucose and 4mML-glutamine, and supplementedwith 15% fetal calf serum, 70 mM b-mercaptoethanol, 50 mg/mL
streptomycin and 50 IU/mL penicillin. All cell lines were cultured at 37C in a humidified atmosphere (5% CO2, 95% air) and tested
negative for mycoplasma contamination.
METHOD DETAILS
Isolation of Rodent Pancreatic Islet Cells
Rodent islets were isolated by collagenase digestion of the pancreas (Gotoh et al., 1987) followed by Histopaque density gradient to
separate them from digested exocrine tissue. At the end of the isolation, islets were hand-picked and incubated overnight at 37C in
RPMI 1640- GlutaMAXmedium (Invitrogen) containing 11.1mMglucose and 2.06mML-glutamine and supplemented with 10% fetal
calf serum (Gibco), 10 mM HEPES, pH 7.4, 1 mM sodium pyruvate, 100 mg/mL streptomycin and 100 IU/mL penicillin. Dissociated
islet cells were obtained by incubating the islets in Ca2+/Mg2+ free phosphate buffered saline, 3 mM EGTA and 0.002% trypsin for
5 min at 37C. For some experiments, rat islet cells were separated by Fluorescence-Activated Cell Sorting (FACS) based on
b cell autofluorescence, as previously described (Jacovetti et al., 2015; Kohler et al., 2012). Sorted islet cells were seeded on plastic
dishes coated with extracellular matrix secreted by 804 G rat bladder cancer cells (804 G ECM), as described elsewhere (ParnaudCell Metabolism 29, 1–14.e1–e6, February 5, 2019 e3
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insulin (dilution 1:100, A0564, Dako) and polyclonal mouse anti-glucagon (dilution 1:1000, Abcam Ab10988) primary antibodies
and goat anti-guinea pig Alexa-Fluor-488 and goat anti-mouse Alexa-Fluor-555 (diluted 1:500, Molecular Probes, Thermofisher
A11073 and A21422, respectively) secondary antibodies. On average, b cell fractions contained 98.1% ± 2.2% insulin-positive cells
and 1.4% ± 1.5% glucagon-positive cells and a cell-enriched fractions contained 5.2% ± 3.5% insulin-positive cells and 91.2% ±
4.3% glucagon-positive cells.
T Lymphocyte Isolation and Culture
Mouse T effector cells were purified from lymphoid tissues of 8 weeks-old NOD/ShiLtJ mice, or miR-155KOmice (or wild type control
littermates) using anti-CD4 and anti-CD25 coated beads (Miltenyi Biotec). Human CD4+ T cells were obtained from 3 anonymous
donors that gave informed consent in accordance with the US National Institutes of Health guidelines. Briefly, buffy coats were
purchased from the Blood Transfusion Center in Lausanne, Switzerland. Peripheral bloodmononuclear cells were isolated by density
centrifugation over a Ficoll-Hypaque gradient (Amersham Bioscience) and washed three times. CD4+ T cells were enriched from
purified mononuclear cells by positive selection using anti-CD4 magnetic microbeads (Miltenyi Biotec). After isolation, murine
CD4+/CD25– T cells and human CD4+ T cells were incubated in RPMI 1640-medium supplemented with 10% fetal calf serum
(previously depleted from serum-exosomes), 100 mg/mL streptomycin and 100 IU/mL penicillin and were stimulated for 72 hr with
20 ng/mL IL-12 and 200 UI/mL IL-2 (R&D system Europe) and Dynabeads T-activator CD3/CD28 (bead-to-cell ratio of 1) (Invitrogen).
After 3 days, media and cells were collected for exosome isolation and/or RNA extraction.
Exosome Isolation and Quantification
Exosomes were isolated by ultra-centrifugation as described previously (Lasser et al., 2012). Briefly, the culturemedia (depleted from
serum-exosomes) of Jurkat cells or primary T cells were collected and centrifuged first at 300 x g for 3 min to pellet cells and then at
2,000 x g for 10 min to discard dead cells. Supernatants were centrifuged at 10,000 x g for 30 min to remove cell debris. Exosomes
were then isolated from the supernatant by ultracentrifugation at 100,000 x g for 2 hr. The pellet containing the exosomeswaswashed
with PBS and re-centrifuged at 100’000 x g for 2 hr. Exosomes were collected in a minimal volume of PBS. The same volume of PBS
(without exosomes) was added to control experimental conditions. Protein concentration was determined by Bradford assay
(BioRad). Recipient MIN6B1 or islet cells were incubated with 50 mg/mL of exosome preparation previously passed on a 0.45 mmfilter
(Figliolini et al., 2014; Guay et al., 2015). The amount of vesicles added to the recipient cells was estimated using the FluoroCet
exosome quantification kit (System Biosciences), which is based on the measurement of the esterase activity associated with exo-
somes. According to these measurements, the recipient cells were exposed to exosome concentrations of about 0.8x1011/mL for
exoT, 0.7x1011/mL for exoNOD and 2 x1011/mL for exo-hT. These concentrations are within the same range as those previously re-
ported in murine and human plasma samples (Matsumoto et al., 2016; Thomou et al., 2017).
Electron Microscopy
Suspensions were adsorbed on 200Mesh Cupper grids coated with forvmar-C for 2 min at RT. The grids were then stained using 2%
phosphotungstic acid for 2min and observed on a transmission electronmicroscope (Jeol 1400 JEM, Tokyo, Japan) equipped with a
Gatan camera (Orius 600) and Digital Micrograph Software.
Nanosight Analysis
Exosome size distribution wasmeasured byNanoparticle Tracking Analysis using theNanoSight system (NanoSight, UK). The device
measures the Brownian motion of particles whose speed of motion, or diffusion coefficient (Dt), is related to particle size through the
Stokes-Einstein equation (Soo et al., 2012).
Western Blot
Proteins from exosome samples or from cellular lysates were migrated on 10% SDS-PAGE gels. Following electrophoresis, proteins
were transferred onto PVDF membranes and blocked at room temperature in Tris-buffered saline/0.3% Tween20 containing 4% of
BSA. The membranes were then incubated overnight at 4C with CD81 (sc-166028), Alix (sc-49268) or TSG101 (sc-6037) antibodies
(Santa Cruz Biotechnology) diluted 1/1000 in 1%BSA. The bandswere detected by chemiluminescence (Pierce) after incubation with
a horseradish peroxidase-conjugated secondary antibody (Bio-Rad).
Image Stream Analysis
Exosomes from Jurkat cells were labelled with 1mM of the lipophilic dye DiD (1,1’-dioctadecyl-3,3,3’,3’-tetramethylindodicarbocya-
nine, 4-chlorobenzenesulfonate salt, Molecular Probes) during the last ultracentrifugation (2 hr at 100,000 x g). The labelled-exosome
pellet was washed twice in PBS before another round of ultracentrifugation (2 hr at 100,000 g). MIN6B1 cells or dissociated rat islet
cells were incubated overnight in the presence of DiD-labelled exoT, before being analyzed on Amnis ImageStreamX Mark II (Merk
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Exosome preparations were re-suspended in 300 mL PBS and spiked with 20 rmol of a synthetic oligonucleotide corresponding to
the mature sequence of miR-29a (Exiqon). Samples were then divided into four aliquots and treated or not with 1% Triton X-100
(Sigma) and incubated with or without RNase A (0.5 U) and RNase T1 (15 U) (Ambion) for 30 min at 37C before RNA extraction.
RNA Assays
RNA was extracted from exosomes, Jurkat, MIN6B1, or islet cells using the miRNeasy micro kit (Qiagen). Mature miRNA levels were
measured using themiRCURY LNAUniversal RTmicroRNA PCR kit (Exiqon) starting from 200 ng of RNA. Cellular miRNA levels were
normalized to miR-7 levels, a miRNA highly expressed in b cells and not modified under the studied conditions. For mRNA measure-
ment, RNA samples were treated with DNase prior to analysis. Profiling of mRNA was performed by Arraystar using Agilent Technol-
ogies and Agilent GeneSpring GX v12.1 software for data analysis. Gene expression levels weremeasured by qPCR using miScript II
RT and SYBR Green PCR kits (Qiagen) and results were normalized to 18S rRNA and Hprt. Finally, GFP levels were assessed using
SYBR Green PCR Master Mix (Life Technologies) with primers specific for GFP and normalized to Gapdh levels. Primer sequences
are provided in Table S5. All qPCR measurements were performed in triplicates and expression levels of miRNAs and mRNAs were
analyzed using the 2–ʌʌC(T) method.
Transfection of Insulin-Secreting Cells
MIN6B1 or dispersed rat islet cells were transfected using Lipofectamine 2000 (Invitrogen) with RNA oligonucleotide duplexes
(Exiqon) corresponding to the mature miRNA sequence (overexpression) or with single-stranded miRCURY LNA inhibitors (Exiqon)
that specifically block the miRNAs (down-regulation). A control miRNA mimic or the control miRCURY LNA inhibitor (Exiqon) were
used as negative controls for miRNA overexpression and down-regulation, respectively.
Insulin Secretion and Content
After incubation for 72 hr in the presence of exosomes (or control PBS), MIN6B1 or dissociated rat islet cells were pre-incubated for
30 min at 37C in Krebs-Ringer bicarbonate buffer (KRBH) containing 25 mM HEPES, pH 7.4, 0.1 % BSA (Sigma-Aldrich) and 2 mM
glucose. The cells were then incubated for 45min in KRBH containing 0.5%BSA and 2 or 20mMglucose. At the end of the incubation
period, media were collected and total cellular insulin contents recovered in acid-ethanol (0.2 mM HCl in 75% ethanol). Insulin levels
were measured using an insulin enzyme immunoassay kit (SPI-Bio). All experiments were performed in triplicates.
Cell Death Assays
MIN6B1 and dissociated islet cells were incubated for 72 hr in presence of T cell exosomeswith or without 0.1mMof the pan caspase
inhibitor Z-VAD-FMK (R&D systems). At the end of the incubation, 1 mg/mL Hoechst 33342 (Invitrogen) was added for 1-2 min. Cells
displaying pycnotic nuclei were scored under fluorescence microscopy (AxioCam MRc5, Zeiss). A minimum of thousand cells were
counted per condition. TUNEL staining on human b cells was performed 48 hr after exposure to exo-hT using the In Situ Cell Death
Detection Kit (Roche) combined to FLEX polyclonal guinea pig anti-insulin (dilution 1:10, IR00261-2, Dako) followed by incubation
with fluorescently labeled goat anti-guinea-pig AlexaFluor 555 antibody (dilution 1:400, A21435, Thermofisher). NFkB translocation
was assessed in MIN6B1 cells after exposure for 48 hr to exoT or for 24 hr to pro-inflammatory cytokines (30 ng/mL INFg, 10 ng/mL
TNFa and 0.1 ng/mL IL-1b). Briefly, MIN6B1 cells cultured on coverslips were fixed, permeabilized, and incubated with a mouse
anti-NFkB p65 antibody (dilution 1:100, sc-372, Santa Cruz Biotechnology) followed by goat anti-mouse Alexa Fluor 488 antibody
(A-11029, Invitrogen). Cell nuclei were stained with Hoechst 33342 (1 mg/mL, Invitrogen). Coverslips were mounted on microscope
glass slides with Fluor-Save mounting medium (VWR International SA) and were visualized with a Zeiss Axiovision fluorescence
microscope. Experiments were performed in single replicates.
Luciferase
MIN6B1 cells were transfected using Lipofectamine 2000 (Invitrogen) with a pGL3 plasmid containing the hsa-miR-155 binding
sequence in the 30 UTR (Skalsky et al., 2007) and the psicheck1 vector (Promega). After 7 hr, culture media of transfected
MIN6B1was changed and exoTwas added for 48 hr or 72 hr. Luciferase activities weremeasured using the Dual-Luciferase Reporter
Assay System (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity to minimize experimental variabilities.
Experiments were performed in triplicates.
Generation of Viral Vectors
The dsAAV-RIP-GFP (AAV-control) was constructed on the backbone of the dsAAV8 plasmid (Nathwani et al., 2006) by replacing the
original LP1 promotor and FIX coding sequences with two multiple cloning sites and inserting the coding sequences for the Rat In-
sulin promotor (RIP) (Addgene plasmid 15029) and green fluorescent protein (GFP) into the multiple cloning site, using the PstI-AccIII
and EcoRI-NotI restriction sites. For the construction of the dsAAV-RIP-GFP-sponge (AAV-sponge), the interrupted palindromic
SanDI (Fermentas) restriction site was used to insert miRNA binding sites for miR-142-3p/-5p, miR-150 and miR-155 (Table S6)
(Kluiver et al., 2012). Viral particles were generated by a triple transfection of HEK293 cells using the 25 kDa linear polyethylenimine
(Polysciences Inc) transfection method (Reed et al., 2006). AAV particles were purified by iodixanol gradient centrifugation as previ-
ous described (Zolotukhin et al., 1999). Viral titers were determined by qPCR with specific primers for the RIP and GFP.Cell Metabolism 29, 1–14.e1–e6, February 5, 2019 e5
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Female NOD/ShiLtJ mice were injected intraperitoneally (i.p.) with 150 mL PBS containing 1 x1012 viral genome particles at the age of
4 weeks. Blood glucose levels were measured once per week on restrained, un-anesthetized animals through tail vein bleeds with a
glucometer and test strips (Life Scan). NOD mice were diagnosed as diabetic if blood glucose levels above 14 mM on 2 consecutive
days. Glucose tolerance test was performed by injecting i.p. 1.5 g glucose per kg of bodyweight on 4 hr fasted NODmice of 10weeks
of age, from the diabetes incidence cohort. Experiments were not performed blinded. One mouse from the AAV-ctl group was
excluded and euthanized at 13 days after injection as it met ethical endpoints (loss of more than 15% of body weight after injection
and showed signs of discomfort).
Histology and Immunohistochemistry
Formalin-fixed pancreatic tissues were embedded in paraffin using standard techniques. 4-mm sections were deparaffinized, rehy-
drated, and incubated with blocking solution. Sections were incubated overnight at 4C with antibodies against GFP (Life Technol-
ogies), followed by signal amplification using the TSA Fluorescein system (Perkin Elmer) or with CD3 antibody (dilution 1:500, A0452,
Dako) followed by the fluorescently labeled secondary antibody goat anti-rabbit AlexaFluor-555 (dilution 1:200, A21428, Molecular
Probes, Thermofisher).
Insulitis score was evaluated by Hematoxylin-Eosin staining of formalin-fixed paraffin embedded pancreata sections. A score
ranging from 0 to 3 was assigned to each identified islet by manual bright field microscope visualization (0: intact islet; 1: peri-insulitic
islet; 2: <50% infiltrated islet area; 3: > 50% infiltrated islet area) (Figure S8).
Immunofluorescence analysis was performed to quantify insulin, glucagon and Cxcl10 positive volume. 5 mm formalin-fixed
paraffin embedded pancreata sections were subjected to double or triple immunofluorescence staining using respectively polyclonal
guinea pig anti-insulin (dilution 1:500, A0564, Dako), monoclonal mouse anti-glucagon (dilution 1:300, MAB1249, R&D Systems) and
polyclonal rabbit anti-murine CXCL10 (dilution 1:25, 500-P129, Peprotech); fluorescently labeled secondary antibodies were goat
anti-guinea pig Alexa-Fluor 488 (dilution 1:500, A11073, Molecular Probes, Thermofisher), goat anti-mouse 647 (dilution 1:500,
A21236, Molecular Probes, Thermofisher) or goat anti-rabbit Alexa-Fluor 594 conjugated (dilution 1:500, A11037, Molecular Probes,
Thermofisher). Stained sections were imaged and analyzed using Leica Sp5 confocal microscopy. Five different focal planes for each
identified islet were scanned at 40Xmagnification. The analysis of positive insulin andCXCL10 volume (mm3) andCXCL10-insulin and
CXCL10-glucagon colocalization rate (%) was quantified using Volocity 6.3 software (Perkin Elmer) by measuring the quantity of in-
sulin and CXCL10 positive fluorescent voxels signal in five different focal planes of each scanned islet and by measuring the ratio
between double positive voxels CXCL10-insulin and CXCL10-glucagon on total insulin and glucagon positive voxels for each
scanned islet.
Immunofluorescence analysis to quantify insulin, glucagon and FoxP3+ cells, was performed by triple immunofluorescence stain-
ing with polyclonal guinea pig anti-insulin (dilution 1:500, A0564, Dako), monoclonal mouse anti-glucagon (dilution 1:300, MAB1249,
R&D Systems) and rat monoclonal anti-murine FoxP3, FITC conjugated (dilution 1:100, 11-5773-82, eBioscience); fluorescent
labeled secondary antibodies goat anti-guinea pig Alexa Fluor 405 conjugated (dilution 1:500, Ab175678, Abcam), goat anti-mouse
594 conjugated (dilution 1:500, A11032, Molecular Probes, Thermofisher), Rabbit anti-fluorescein 488 conjugated (dilution 1:80,
A11090, Molecular Probes, Thermofisher) and tertiary antibody goat anti-rabbit 488 conjugated (dilution 1:200, A11034, Molecular
Probes, Thermofisher), were used. Stained sections were imaged and analyzed using Leica Sp5 confocal microscopy as described
above and FoxP3+ cells were quantified through manual cell count.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are expressed as mean ± SD. Statistical significance was determined using parametric unpaired two-tailed Student’s t test or,
for multiple comparisons, with one-way analysis of variance (ANOVA) of the means, followed by post-hoc Dunnett or Tukey test, or
unparametric Mann-Whitney U test (Graph Pad Prism6). The percentage of nondiabetic mice was calculated by Kaplan–Meier sur-
vival analysis andwere compared using the Log rank (Mantel-Cox) test. p values less than 0.05 (p < 0.05) were considered statistically
significant.
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